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httpcense.Abstract Setting: About 1–3% of patients with diagnosed chronic obstructive pulmonary disease
(COPD) is predicted to have alpha1-antitrypsin deﬁciency (A1ATD).
Objective: To clinically evaluate and increase recognition of AATD in patients with COPD.
Materials and methods: Sixty COPD patients were diagnosed on the basis of clinical and pul-
monary function tests. They fulﬁlled the inclusion criteria and divided into group (A) COPD above
40 years (30 cases) and group (B) COPD below 40 years (30 cases). All patients were subjected thor-
ough history taking, radiological examination, blood gas analysis and quantitative measurements of
serum alpha-1 antitrypsin by radio-immunoassay.
Results: Mean ages of the groups A and B were (61.87 ± 6.04, 34.17 ± 2.75) respectively with (p
value <0.001). The mean serum levels of alpha 1 antitrypsin in groups A and B were
(185.03 ± 23.00 with only one case deﬁcient and 177.53 ± 49.94 with only four cases deﬁcient)
respectively without statistical signiﬁcance. There is signiﬁcant relationship between the age of
the patient and A1ATD, where in deﬁcient patients mean age was 39.63 ± 13.66, and in normal
patients mean age was 50.18 ± 12.06) with (p value 0.02). There is also signiﬁcant relationship
between family history and A1ATD, where in deﬁcient patients 50% of cases (four cases) had posi-
tive family history, in contrast to 11.61% of cases (13 cases) of normal patients (p value 0.03). There
is no signiﬁcant difference between the deﬁcient and normal group as regards gender distribution,
smoking history, symptomatic presentations, physical signs, radiological picture, pulmonary func-
tion tests and blood gas parameters.
Conclusion: Emphysema at an early age, non smokers with positive family history is a clinical
feature suggestive of A1ATD.
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Alpha1-antitrypsin (AAT) deﬁciency, ﬁrst described in 1963, is
one of the most common inherited disorders among white per-
sons. Its primary manifestation is early-onset of panacinar
emphysema. In adults, alpha1-antitrypsin deﬁciency leads tois. Production and hosting by Elsevier B.V.
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72 M. Sh. Badawy et al.chronic liver disease in the ﬁfth decade. As a cause of emphy-
sema, it is seen in nonsmokers in the ﬁfth decade of life and
during the fourth decade of life in smokers.
Symptoms of alpha1-antitrypsin (AAT) deﬁciency emphy-
sema are limited to the respiratory system. Dyspnea is the
symptom that eventually dominates alpha1-antitrypsin deﬁ-
ciency. Similar to other forms of emphysema, the dyspnea of
alpha1-antitrypsin deﬁciency is initially evident only with
strenuous exertion. Over several years, it eventually limits even
mild activities.
No single physical sign conﬁrms a diagnosis of alpha1-anti-
trypsin deﬁciency emphysema. Signs characteristic of increased
respiratory work, airﬂow obstruction, and hyperinﬂation even-
tually develop but are dependent on the severity of emphysema
at the time of diagnosis [1].
The most common form of alpha1-antitrypsin deﬁciency is
associated with allele Z, or homozygous PiZ (ZZ). Serum levels
of alpha1-antitrypsin in these patients are about 3.4–7 lmol/L,
10–15% of normal serum levels. Serum levels greater than
11 lmol/L appear to be protective. Emphysema develops in
most (but not all) individuals with serum levels less than
9 lmol/L.
MZwas associatedwith reduced pulmonary function in indi-
viduals with clinically established COPD, whereas SZ and ZZ
were associated with reduced pulmonary function in smokers.
The presence of the alpha(1)-antitrypsin MZ genotype may in
certain circumstances produce marked aggravation of airway
obstruction in individuals prone to develop COPD [2].
Aim of the work
To clinically evaluate and increase recognition of AATD in pa-
tients with COPD.
Materials and methods
Patients with stable chronic obstructive pulmonary disease
(COPD), attending to outpatient chest clinic or admitted to
the chest department in the Sohag University Hospital were
enrolled in the study.
Duration of the study: 1 year.
The study was approved by the faculty of the scientiﬁc ethics
committee. Written informed consent was taken from all
patients.
The patients were subdivided into four groups:
 Group 1: COPD above 40 years (30 cases).
 Group 2: COPD below 40 years (30 cases).
These groups of patients were diagnosed using the GOLD
(2007) guideline. It includes clinical diagnosis of COPD that
should considered in any patient who has dyspnea, cough or
sputum production and or history of exposure to risk factors
for the disease. The diagnosis should be conﬁrmed with pul-
monary function test with post bronchodilator FEV1/FVC%
less than 70% and FEV1% predicted less than 12% [3].
Exclusion criteria:
(1) COPD in acute exacerbation.
(2) Positive reversibility test as improvement of post bron-
chodilator FEV1 more than 12% on pulmonary func-
tion test.All patients subjected to:
(1) Comprehensive history: focused in:
– Age.
– Gender.
– Smoking history, tobacco exposure.
– Respiratory symptoms: Age of onset of symptoms; cough,
expectoration, and dyspnea (its grade, duration); fre-
quency of acute exacerbations in the last year.
– Symptoms of sinusitis
- Associated diseases: hepatological, dermatological
symptoms.
- Family history of similar disease.
(2) Clinical examination:
– General examination: focused in cyanosis, lower limb
edema, clubbing of ﬁngers.
– Chest examination: inspection, palpation, percussion,
auscultation.
– Abdominal examination: focused in hepatomegaly.
(3) Radiological evaluation:
– Chest
– X-ray (postero-anterior, lateral view)
(4) Pulmonary function tests:
They were performed with a spirometer of computer pro-
cessing (Jaeger Master Screen Diffusion, Viasys Healthcare,
Gmbh, Hochberg, Germany).
Age, height and weight of the subjects were entered in the
spirometer. The spirometer gives two values: one is the ex-
pected value and the other is the actual value. The expected
values are based on the height, age and weight of the subjects.
FVC, FEV1, FEV1/FVC, were measured.
Bronchodilator reversibility: The subject received nebulized
short acting B2 agonist (2.5 mg salbutamol) then the test was
repeated after 10–15 min (the patient had not received bron-
chodilators in the past 12 h).
The percentage improvement in FEV1 can be calculated as
follows:(Postbronchodilator FEV1  prebronchodilator
FEV1)/prebronchodilator FEV1 · 100)
A positive response to bronchodilators is an increase in
FEV1 from baseline that is more than 200 ml and more than
12% of the prebronchodilator value.
Technique of pulmonary function tests: The actual values
(FVC, FEV1, FEV1/FVC) are based on the maximal inspira-
tion and expiration of the subjects. The pulmonary function
test was conducted by sitting the subject comfortably in a
chair. Sterilization of the mouthpiece was done before use.
The subjects were asked to perform maximum inspiration fol-
lowed by maximal exhalation. Three tests were performed and
the subjects were assisted to improve their efforts. The best of
the three performances of FVC, FEV1, FEV1/FVC was taken
[4].
(5) Arterial blood gases:
It was performed with ABL 700 SERIES. Arterial blood
gas analysis refers to the measurement of PH and the partial
pressures of oxygen (O2), SO2, carbon dioxide (CO2) in arterial
blood and HCO3.
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tient’s hand with the wrist extended. Identify the radial artery
by palpating the pulse; choose a site where the pulse is prom-
inent. Clean the sampling site with an alcohol wipe and wait
until dry. Then insert the needle slowly. When the needle is
in the artery a ﬂash of pulsatile blood will appear and obtain
at least 3 ml of blood before withdrawing the needle.
(6) Quantitative measurement of alpha-1-antitrypsin level in
blood:
All patients of the two groups subjected to quantitative
measurements of serum level of alpha 1 antitrypsin.
2 ml of whole blood is taken from the patient in a sterile
collection tube, the specimen send to lab within 24 h, then cen-
tral centrifugation done, alpha 1antitrypsin serum level mea-
sured by radial immunoassay, the values expressed as
milligrams per deciliter.
 Reference values between 150 and 350 mg/dl are considered
normal values, values below 150 mg/dl are considered deﬁ-
cient [5].
 The PI type can be predicted from the serum levels:
 PiMM: 100% (normal)
 PiMS: 80% of normal serum level of A1AT
 PiSS: 60% of normal serum level of A1AT
 PiMZ: 60% of normal serum level of A1AT, mild deﬁciency
 PiSZ: 40% of normal serum level of A1AT, moderate
deﬁciency
 PiZZ: 10–15% (severe alpha 1-antitrypsin deﬁciency) [6]
Statistical methods used for data analysis
The data subjected to statistical analysis and tabulation using
SPSS version 18. p Value is considered signiﬁcant if less than
0.05 then the results were presented to fulﬁll the objectives of
the study.Table 1 Personal characteristics of studied patients.
Total Above 40 years Gr
Age
Mean (SD) 153.02 (10.07) 61.87 (6.04)
Range 53–72
Gender
Female 8 (13.33%) 4 (13.33%)
Males 52 (86.67%) 26 (86.67%)
Smoking history
No 6 (10%) 1 (3.33%)
Yes 54 (90.00%) 29 (96.67%)
Smoking type
No 6 (10%) 1 (3.33%)
Cigarette 34 (56.67%) 17 (56.67%)
Goza 9 (15%) 9 (30.00%)
Mixed 11(18.33%) 3 (10%)
Smoking index
No 6 (10%) 1 (3.33%)
Mild 0 0
Moderate 4 (7.02%) 0
Heavy 47 (82.46%) 26 (96.30)Results
The study was done at the chest department of Sohag Univer-
sity hospital in year 2011 and included 60 patients categorized
in two groups:
 1st group: included 30 cases of COPD whose onset of symp-
toms start above age of 40
 2nd group: included 30 cases of COPD whose onset of
symptoms start below age of 40. In comparison between
two groups (COPD below 40 years/COPD above 40 years)
The age in the 2nd group ranged from 28 to 39 years with
mean age of 34.17(SD 2.75), while in 1st group, it ranged from
53 to 72 years with mean value of 61.87 (6.04 SD), there were
signiﬁcant differences between the two groups as regards the
age (p value <0.001) (Table 1).
The distribution of patients as regards the gender showed
no signiﬁcant difference between the two groups, where both
groups matched in 26 (86.67%) male cases, and four
(13.33%) female cases (Table 1).
As regards smoking history, in 1st group, 29 cases (96.67%)
were smokers, of which 26 cases (96.3%) were heavy smokers,
predominately cigarette smokers(17 cases) (56.67%) where the
rest showed (one case did not smoke, nine cases were goza
smokers, three cases mixed cigarette and goza smokers),while
in 2nd group, 25 cases (83.33%) were smokers, of which 21
(70%) cases were heavy smokers, predominately cigarette
smokers (17 cases (56.67%) (Table 1).
As regards the symptoms between the two groups, there
was similarity in cough, expectoration and exertional dyspnea
where all patients in both groups experienced symptoms (30
cases (100%) in each group). Also no signiﬁcant differences
in heamoptysis between the two groups, only two cases
(6.67%) in the 2nd group with no cases in the 1st group















Table 2 Symptoms of patients with COPD.
Total Above 40 years Below 40 years p Value
Age of onset
Mean (SD) 40.93 (8.24) 47.6 (5.95) 34.27 (3.26) <0.0001
Cough and expectoration
No 0 0 0
Yes 60 (100.00%) 30 (100%) 30 (100%)
Dyspnea
No 0 0 0
Yes 60 (100.00%) 30 (100%) 30 (100%)
Haemoptysis
No 58 (96.67%) 30 (100%) 28 (93.33%) 0.15
Yes 2 (3.33%) 0 2 (6.67%)
Symptoms of sinusitis
No 45 (75.00%) 27 (90.00%) 18 (60.00) 0.007
Yes 15 (25.00%) 3 (10.00%) 12 (40.00)
Hepatological symptoms
No 59 (98.33%) 29 (96.67%) 30 (100.00) 0.31
Yes 1 (1.67%) 1 (3.33%) 0
Family history
No 52 (86.67%) 29 (96.67%) 23 (76.67%) 0.02
Yes 8 (13.33%) 1 (3.33%) 7 (23.33%)
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(10%) while in 2nd group were 12 (40%). There was signiﬁcant
difference between both groups as regards sinusitis (p: 0.007),
but no signiﬁcant difference between the two groups in hepa-
tological symptoms as only one case (3.33%) in the 1st group
show hepatological symptoms with no cases in the 2nd group
(Table 2).
In the 1st group, one case (3.33%) showed a positive family
history for COPD. while in the 2nd group, seven casesTable 3 General and chest examination of studied patients.
General examination Total Abo
Cyanosis
No 36 (60.00%) 20 (
Yes 24 (40.00%) 10 (
Clubbing
No 60 (100.00%) 30 (
Yes 0 0
LL edema
No 55 (91.67%) 27 (




Yes 60 (100.00%) 30 (
Wheezes
No 34 (56.67%) 23 (
Yes 26 (43.33%) 7 (2
Cripitations
No 0 0
Yes 60 (100.00%) 30 ((23.33%) showed positive family history. There were signiﬁ-
cant differences between the two groups in family history (p:
0.02).
The general examination of both groups was different. 10
cases (33.33%) of 1st group were cyanosed, while 14
(46.67%) of 2nd group were cyanosed. Neither cases of both
groups showed ﬁnger clubbing. Three cases (10%) of the 1st
group and two cases (6.67) of second group showed lower limb
edema (Table 3).ve 40 years Below 40 years p Value












Table 5 Pulmonary function tests and bl. Gases, serum alpha 1antitrypsin level and predicted PI of patients with COPD.
Total Above 40 years Below 40 years p Value
FEF1
Mean (SD) 41.52 (13.32) 41.97 (9.71) 41.1 (16.23) 0.81
FVC
Mean (SD) 68.71 (19.74) 67.13 (18.62) 70.22 (20.97) 0.56
FEV1/FVC
Mean (SD) 50.39 (9.47) 50.98 (8.35) 49.11 (10.52) 0.47
PO2
Mean (SD) 67.76 (16.07) 71.85 (19.17) 63.68 (11.11) 0.048
PCO2
Mean (SD) 43.80 (11.93) 43.64 (9.41) 43.96 (14.19) 0.91
Alpha 1antitrypsin
Mean (SD) 181.28 (36.84) 185.03 (23.00) 177.53 (46.94) 0.43
Predicted PI
MM 55 (91.67%) 29 (96.67%) 26 (86.67%)
MS 1 (1.67%) 0 1 (3.33%) 0.48
MZ, SS 3 (5.00%) 1 (3.33) 2 (6.67%)
ZZ 1 (1.67%) 0 1 (3.33%)
Table 4 Radiological examination of patients with COPD.
Total Above 40 years Below 40 years p Value
Chest X-ray
Hyperinﬂation
No 3 (5.00%) 0 1(3.33%)
Yes 57 (95.00%) 30 (100%) 29(96.66%)
Hyperinﬂation with bronchiectesis
No 59 (98.33%) 30 (100.00%) 29 (96.67%) 0.31
Yes 1 (1.67%) 0 1 (3.33%)
Bronchiectatic changes
No 60 (100.00%) 30 (100.00%) 30 (100.00%)
Yes 0 0 0
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groups showed signs of hyperinﬂation, and basal cripitations
(30 cases (100%) of each group). But only SEVEN cases
(23.33%) of the 1st group were wheezy, and 19 cases
(63.33%) of the second group were wheezy, (p: 0.002). There
is signiﬁcant difference in wheezes between the two groups
(Table 3).
Radiological evaluation of patients of the two groups
showed insigniﬁcant difference, all 30 cases (100%) of the 1st
group show signs of hyperinﬂation in chest X-ray; while, 29
cases (96.66) of the 2nd group showed signs of hyperinﬂation
in chest X-ray, and only one case (3.33%) showed hyperinﬂa-
tion with bronchiectatic changes in chest X-ray. C-T chest was
done only for three cases in 2nd group and showed emphyse-
matous bullae at both lungs (Table 4).
The pulmonary function tests of both groups showed
obstructive pattern which was more worse in the 2nd group.
In the 1st group the mean FEV1: 41.94(SD 9.71), mean
FVC: 67.13(SD 18.62) and mean FEV1/FVC: 50.98 ± 8.35’
while in the 2nd group the mean FEV1: 41.1(SD 16.23), mean
FVC: 70.22 ± 20.97, and mean FEV1/FVC: 49.11(10.52) with
no signiﬁcant difference between both groups. (Table 5) Thearterial blood gases of both groups were insigniﬁcant. As all
cases in both groups were in the stable state, for the 1st group,
mean PO2: 71.85 ± 19.17, mean PCO2: 43.96 ± 9.41, and for
the 2nd group, mean PO2: 63.68 ± 11.11, and mean PCO2:
43.96 ± 14.19.
The mean serum level alpha 1 antitrypsin in the 1st group
was 185.03 mg/dl ± 23.00), from which only one case is deﬁ-
cient (A1AT value: 140 mg/dl), in contrast to the 2nd group,
the mean serum level A1AT was less, 177.53 mg/dl ± 49.94
and four cases were deﬁcient with values (12.5, 105, 109.4,
126.3 mg/dl) without signiﬁcant difference between both
groups (Table 5).
For the deﬁcient patient group, the mean serum A1AT level
was 101.53 (SD 41.37), while the mean serum A1AT level for
the normal group: 189.46 (SD 25.34) (p value: <0.001).
The distribution of deﬁciencies in the two groups was as
follows:
 One case (20%) in 1st group (COPD above 40 years).
 Four cases (80%) in 2nd group (COPD below 40 years)
The values of deﬁciencies were as follows:
76 M. Sh. Badawy et al. One case with severe deﬁciency (Serum A1AT level <50%
normal) of values: (12.5 mg/dl in 1st group COPD above
40).
 Four cases with partial deﬁciency (Serum A1AT level
>50% normal) of values: (140, 126.3, 105, 109.4, in the
2nd group of patients COPD below 40).
Discussion
Alpha-1 antitrypsin deﬁciency (A1ATD) is a hereditary reces-
sive autosomal disease caused by mutations in the AAT gene.
This disease is characterized by abnormally low AAT concen-
trations in plasma, which carries a high risk of the develop-
ment of early onset pulmonary emphysema [7].
Alpha-1 antitrypsin deﬁciency (A1ATD) is the only known
genetic risk factor that has been associated with emphysema.
About 1–2% of people with emphysema have this disorder,
The severity of airﬂow obstruction in AAT deﬁciency, age at
presentation of respiratory symptoms, physiologically demon-
strable airﬂow obstruction vary widely and are strongly related
to tobacco smoking .
This study showed that ﬁve patients had alpha 1 antitrypsin
deﬁciency from 60 studied patients with COPD, (preva-
lence = 8.33%), this agrees with Edwin K., and Robert A.
that found, AAT deﬁciency is recognized in less than 10% of
persons in whom a diagnosis would be expected on the basis
of screening studies in COPD patients [8]. Also in Tunisia,
Denden et al. who investigated 120 patients with obstructive
lung disease and found 6/120 patients carried an AAT deﬁcient
allele [9].
In our study the A1AT deﬁciency was more in COPD be-
low 40 (4/30) (prevalence = 13.33%), and less prevalent in pa-
tients with COPD above 40 (1/30) (prevalence = 3.33%). This
is in agreement with Edwin et al., who found that most com-
mon pulmonary presentation of AAT deﬁciency is the severe
form, early-onset emphysema in adults [8].
There is signiﬁcant relationship between the age of the pa-
tient and A1AT deﬁciency, age of deﬁcient patients about
40 years, this is in agreement with Cox et al. who stated that
onset of respiratory disease in patients with AATD is between
age 40 and 50 years and was reported, emphysema in children
with AATD is extremely rare [10].
The present study showed a signiﬁcant relationship between
the family history of COPD and alpha1-antitrypsin deﬁciency,
this is consistent with Silverman who found increased risk to
current or ex-smoking ﬁrst-degree relatives of early-onset
COPD propend for reduced FEV1, chronic bronchitis and spi-
rometric evaluation of bronchodilator responsiveness has been
demonstrated. These data strongly support the genetic basis
for the development of COPD and the potential for gene-by-
environment interaction [11].
A study done by Sitkauskiene and co-workers [12], which
was conducted in 1167 COPD patients in Lithuania, the results
were Ninety-one AAT deﬁciency genotypes (40 MZ, 39 MS, 1
SS, 3 SZ and 8 ZZ) identiﬁed. This demonstrates a signiﬁcant
increase of MZ, MS genotypes in COPD patients. Where in the
present study the levels of alpha 1 antitrypsin in deﬁciency
group were not directed toward the homozygous ‘‘Z’’ allele
which is the commonest deﬁciency allele in our geographicalarea, but that heterozygous deﬁciency allele ‘‘M,S,Z’’ is the
most prevalent .
According to De Serres [13] AAT deﬁciency (PI ZZ type) is
rare or absent in Asian and black populations, while, within
Europe, the highest prevalence of the Z allele is observed in
northern and western countries, gradually decreasing through-
out Europe, with the lowest prevalence in eastern Europe [13].
In the 1970s the largest unbiased nationwide AAT deﬁ-
ciency screen of newborns was carried out by Laurell and Sve-
ger in Sweden. Of 200,000 individuals studied 127 were
identiﬁed as being deﬁcient to alpha 1 antitrypsin and homozy-
gous for the Z allele [14]. This is not in concordance with the
present study that heterozygous Z,S,M allels are more preva-
lent, but the geographical difference may be the explanation.
On the basis of a large survey of studies regarding the
occurrence of AAT deﬁciency worldwide, De Serres estimates
that worldwide, 117 million individuals have the PI\MS and
PI\MZ phenotypes and that 3.4 million individuals have the
PI\ZZ, PI\SZ, or PI\SS phenotype [13].
Only four patients were A1AT deﬁcient from 30 cases with
COPD whose age at onset below 40, this reﬂects other unrec-
ognized genetic predisposition to development of COPD in
young age, also reﬂects the link between exposure of children
to particulate matter (air pollution from fossil fuels, environ-
mental tobacco smoke, and burning of solid fuels such as bio-
mass) and increased vulnerability to respiratory diseases in
adulthood, this is in agreement with Jonathan Grigg et al. [15].
Cigarette smoking is the major risk factor for development
of emphysma. The present observations accord with the ﬁnd-
ings of others where most of patients had a history of smoking.
Exposure of the lungs to tobacco smoke markedly increases
the number of pulmonary alveolar macrophages which become
activated to give increased proteolytic activity and also to se-
crete a chemotactic factor which attracts leucocytes to the
lungs. There is an increase in the elastolytic load in the lungs,
and at the same time the inhibitory activity of alpha 1 antitryp-
sin in the alveoli greatly decreased, according to Gadek et al.
[16]. This decrease is the result of direct oxidation of its reac-
tive center by free radicals in the smoke and also by oxygen
radicals released from the activated leucocyte. This increased
production of elastase, together with a decrease in its inhibi-
tory activity, results in an attack on the lower respiratory tract
and the development of emphysema [17].
There is no signiﬁcant difference between the A1AT deﬁ-
cient and normal patients with COPD as regards the gender
distribution, smoking history, symptomatic presentations,
physical signs, radiological picture, the pulmonary function
tests and arterial blood gases, this is in agreement with Sveger’s
study, globally AAT deﬁciency is an under-diagnosed condi-
tion; many being diagnosed as non-responsive asthmatics or
chronic obstructive pulmonary disease (COPD) sufferers.[14]
Also Edwin and Robert show that, AAT deﬁciency remains
undiagnosed in many patients, and there are often long delays
between the onset of respiratory symptoms and diagnosis, and
the condition is frequently not diagnosed [8].Conclusion
Emphysema at an early age, non smoker with positive family
history is a clinical feature suggestive for A1ATD.
Clinical features of alpha1 antitrypsin deﬁciency in COPD 77Although AATD is one of the most common inherited con-
ditions, it is under diagnosed. There is strong relationship be-
tween age, family history of COPD patient and A1AT
deﬁciency, more common in young age.
Homozygous Z allele is not the commonest deﬁciency allele
in our geographical area but the heterozygous alleles M,S,Z
and homozygous S allele are the more prevalent ones.
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